In any case, it would be preferable to exclude these miRNAs from the panel of miRNAs used for characterizing angiogenesis and for hypoxia to be analyzed to evaluate the progression of the disease in patients with IDH-mutated gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.